Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by ValuEngine

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday, ValuEngine reports.

A number of other research analysts also recently commented on the company. Cowen reaffirmed a “buy” rating and issued a $80.00 price target on shares of Esperion Therapeutics in a research note on Thursday, July 18th. BidaskClub downgraded Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 31st. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, August 29th. Goldman Sachs Group raised Esperion Therapeutics from a “sell” rating to a “neutral” rating and dropped their price target for the company from $55.00 to $45.00 in a research note on Monday, September 16th. Finally, Stifel Nicolaus dropped their price target on Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Esperion Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $71.60.

ESPR stock traded up $0.03 during midday trading on Wednesday, reaching $37.52. The company had a trading volume of 164,277 shares, compared to its average volume of 389,809. The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -4.98 and a beta of 1.89. The stock has a 50 day moving average price of $36.79 and a 200-day moving average price of $43.11. Esperion Therapeutics has a 1-year low of $33.13 and a 1-year high of $60.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.65 and a quick ratio of 5.65.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($2.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.86) by ($0.15). The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $1.05 million. The firm’s quarterly revenue was up 9720.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.71) earnings per share. As a group, research analysts anticipate that Esperion Therapeutics will post -3.02 earnings per share for the current year.

In other Esperion Therapeutics news, major shareholder Target N. V. Biotech bought 50,000 shares of the stock in a transaction on Tuesday, July 23rd. The stock was purchased at an average price of $42.65 per share, with a total value of $2,132,500.00. Following the completion of the purchase, the insider now owns 3,572,964 shares in the company, valued at $152,386,914.60. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Timothy M. Mayleben bought 2,500 shares of the stock in a transaction on Friday, September 6th. The shares were acquired at an average cost of $35.25 per share, with a total value of $88,125.00. Following the purchase, the chief executive officer now owns 76,015 shares of the company’s stock, valued at approximately $2,679,528.75. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 142,500 shares of company stock valued at $5,291,825. 7.70% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ESPR. NumerixS Investment Technologies Inc acquired a new position in Esperion Therapeutics during the first quarter worth about $280,000. Dynamic Technology Lab Private Ltd acquired a new position in Esperion Therapeutics during the first quarter worth about $329,000. Marshall Wace LLP acquired a new position in Esperion Therapeutics during the first quarter worth about $186,000. Marshall Wace North America L.P. acquired a new position in Esperion Therapeutics during the first quarter worth about $164,000. Finally, Xact Kapitalforvaltning AB acquired a new position in Esperion Therapeutics during the second quarter worth about $203,000.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

See Also: What is a stock split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.